-
2023-504013-68-00
1
2024-09-06
Advanced or Metastatic Prostate Cancer
-
2023-504139-42-00
7
2024-09-06
Advanced or metastatic solid tumors
-
2023-506159-12-00
10
2024-09-06
Generalized Myasthenia Gravis
-
2022-502408-57-00
5
2024-09-04
Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients hav
-
2024-510917-14-00
5
2024-09-03
Angelman Syndrome
-
2023-510128-66-00
5
2024-09-02
Participants with treatment-naïve metastatic squamous Non-small Cell L
-
2024-517204-11-00
4
2024-08-30
microsatellite stable (MSS) colorectal cancer with liver-dominant meta
-
2022-502757-34-00
1
2024-08-20
Advanced solid tumors
-
2024-515297-27-00
5
2024-08-14
colon carcinoma
-
2023-506503-26-00
5
2024-07-31
Polyneuropathy, Inflammatory Demyelinating, Chronic
-
2023-509096-16-00
6
2024-07-31
Moderately to Severely Active Crohn’s Disease
-
2024-514882-20-00
8
2024-07-31
spasticity
-
2023-508260-30-01
5
2024-07-30
Patients with poor prognostic OVARian cancers based on the tumor prima
-
2024-515788-73-00
4
2024-07-30
MICROSATELLITE STABLE (MSS) METASTATIC COLORECTAL CANCER AND
A HIGH IM
-
2024-514083-31-00
4
2024-07-26
squamous cell anal carcinoma
-
2024-512872-36-00
5
2024-07-25
obstetric_pathological delivery
-
2023-507684-19-00
5
2024-07-24
FGFR+ Intermediate-risk Non-muscle Invasive Bladder Cancer
-
2024-512869-14-00
5
2024-07-22
Diseases [C] - Virus Diseases [C02]
-
2023-509905-62-00
5
2024-07-19
Lower limb trauma requiring immobilisation
-
2023-505298-34-00
4
2024-07-18
Patients with dMMR/MSI (non-colorectal/non-endometrial) locally advanc
-
2024-514107-34-00
4
2024-07-18
BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER
-
2023-504910-31-00
5
2024-07-15
Non-small Cell Lung Cancer (NSCLC)
-
2023-507641-29-00
4
2024-07-15
Locally Advanced or Metastatic Solid Tumors
-
2023-504962-52-00
5
2024-07-10
Triple negative breast cancer.